Over 80% of men experience significant hair loss during their lifetimes. Male Pattern Hair Loss (MPHL) is often a result of androgenetic alopecia, an inherited genetic condition prevalent in up to half the global population.
However, genetic doesn’t mean untreatable. Individuals who experience hair loss have two useful medications available: minoxidil and finasteride. Both can effectively support the regrowth of lost hair and slow continued balding. Understanding the differences between minoxidil and finasteride, including their capabilities, application methods, and use cases, can help you pinpoint the most effective treatment to reduce hair loss.
Minoxidil is a topical treatment you apply directly to your scalp to stimulate hair growth. It works by:
Minoxidil is often used in the earlier stages of hair loss, when you notice initial thinning or receding in your crown area. It comes in both foam and liquid varieties in 2% and 5% concentrations.
Minoxidil’s 5% formula offers more stimulation, leading to a thicker, fuller-appearing head of hair. However, this medication is topical, meaning its effects are local to the scalp tissue, unlike finasteride, which is a systemic medication affecting the whole body.
Finasteride is an oral medication that can slow or halt hairline recession and prevent further hair loss. Internally, it:
DHT is the most significant hormonal factor associated with MPHL. As men bald, the amount of DHT receptors in their hair follicles increases alongside overall DHT concentration on the scalp.
By reducing DHT production by over 90%, finasteride can lead to a hair count reversal, meaning more new strands growing in than falling out.
From a high level, the main differences between minoxidil vs finasteride for hair loss include:
Both minoxidil and finasteride are lifelong commitments. Stopping either treatment negates its positive effects and can reactivate pattern hair loss, making it essential to find the right medication for sustained regrowth.
Several factors weigh in on whether minoxidil vs finasteride is the right choice for you.
Counsel offers a streamlined approach to hair loss treatment that starts with a chat with medical AI. The AI reviews your hair loss pattern, relevant health history, and current symptoms to provide personalized insights and determine eligibility. This initial assessment helps clarify which treatment options may be most suitable for your situation.
A board-certified doctor then joins the same conversation to further review your case, answer questions, and discuss your treatment plan, including the prescription medication. This approach removes traditional barriers such as long wait times, multiple appointments, and repeated explanations, allowing you to start treatment faster and with confidence.
Unlike traditional hair loss treatment, Counsel's chat-based interface provides patients with continuous support anytime, anywhere. Members regularly check in with a doctor to evaluate progress and discuss any changes to the treatment plan. Plus, Counsel supports members beyond just hair loss in one unified place. When other health concerns arise, such as new symptoms, or members are curious about optimizing their health by taking action on their latest blood tests, Counsel provides actionable guidance and care.
NIH. Male pattern hair loss: Can developmental origins explain the pattern? https://pmc.ncbi.nlm.nih.gov/articles/PMC10946844/.
Journal of drugs in dermatology. Addressing the root causes of female hair loss and non-pharmaceutical interventions. https://pubmed.ncbi.nlm.nih.gov/40627570/.
NIH. Androgenetic alopecia. https://www.ncbi.nlm.nih.gov/books/NBK430924/.
NIH. Minoxidil. https://www.ncbi.nlm.nih.gov/books/NBK482378/.
NIH. Finasteride. https://www.ncbi.nlm.nih.gov/books/NBK513329/.
NIH. Male androgenetic alopecia. https://www.ncbi.nlm.nih.gov/books/NBK278957/.
Journal of the American Academy of Dermatology. A one-year observational study with minoxidil 5% solution in Germany: Results of independent efficacy evaluation by physicians and patients. https://www.jaad.org/article/S0190-9622(03)03692-2/.
National Center for Biotechnology Information. Comparative Efficacy of Topical Finasteride (0.25%) in Combination with Minoxidil (5%) Against 5% Minoxidil or 0.25% Finasteride Alone in Male Androgenetic Alopecia: A Pilot, Randomized Open-Label Study. https://pmc.ncbi.nlm.nih.gov/articles/PMC10495069/.
NIH. Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A systematic review and continuous bayesian network meta-analysis. https://pmc.ncbi.nlm.nih.gov/articles/PMC9900126/.
The Counsel Health editorial team is a multidisciplinary group of writers and editors dedicated to delivering clinically grounded, evidence-based health information. Their work is informed by real-world care delivery and guided by physician expertise, ensuring content is accurate, accessible, and trustworthy. By translating complex medical topics into clear, practical guidance, the team helps readers understand their health, explore care options, and make informed decisions in a rapidly evolving healthcare landscape.

Dr. Rishi Khakhkhar is CMO at Counsel Health. A practicing emergency physician and founding team member, he leads the clinical team in building best-in-class asynchronous care models. Previously, he served as Medical Director of Mount Sinai’s Virtual Urgent Care, the health system’s largest telemedicine service, and led emergency department operations for Hospital-at-Home while supporting mobile integrated health initiatives across the care continuum.
Our content is created for informational purposes and should not replace professional medical care. For personalized guidance, talk to a licensed physician. Learn more about our editorial standards and review process.